Valuation: Healios K.K.

Market Cap 34.56B 213M 186M 172M 158M 298M 20.5B 305M 2.05B 807M 10.04B 799M 782M P/E 2026 *
-7.03x
P/E 2027 * -12.5x
Enterprise Value 34.3B 211M 185M 170M 157M 296M 20.34B 303M 2.04B 801M 9.96B 793M 776M EV / Sales 2026 *
57x
EV / Sales 2027 * 3.95x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
1 day-4.12%
1 week-1.92%
Current month+1.19%
1 month-6.23%
3 months-30.81%
6 months-20.00%
Current year-6.57%
1 week 249
Extreme 249
285
1 month 235
Extreme 235
285
Current year 234
Extreme 234
483
1 year 234
Extreme 234
747
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 72 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-4.12%-1.92%-63.11%-17.42% 222M
-7.17%-4.39%+45.51%+79.00% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-2.58%+30.67%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+168.44%+306.37% 16.09B
-6.91%-5.83%+26.53%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
Average -2.91%+0.31%+30.38%+163.68% 24.07B
Weighted average by Cap. -2.92%-0.73%+40.49%+144.64%

Financials

2026 *2027 *
Net sales 602M 3.71M 3.24M 2.99M 2.76M 5.2M 357M 5.31M 35.75M 14.06M 175M 13.93M 13.62M 9.12B 56.16M 49.08M 45.29M 41.75M 78.68M 5.41B 80.43M 541M 213M 2.65B 211M 206M
Net income -4.77B -29.38M -25.68M -23.7M -21.84M -41.17M -2.83B -42.08M -283M -111M -1.39B -110M -108M -2.94B -18.14M -15.85M -14.63M -13.48M -25.41M -1.75B -25.97M -175M -68.76M -855M -68.11M -66.62M
Net Debt -260M -1.6M -1.4M -1.29M -1.19M -2.24M -154M -2.29M -15.42M -6.07M -75.47M -6.01M -5.88M 1.46B 9.01M 7.87M 7.27M 6.7M 12.62M 868M 12.9M 86.85M 34.16M 425M 33.84M 33.1M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-07-17 JP¥256.00 -4.12% 1,849,300
26-07-16 JP¥267.00 -4.64% 1,600,300
26-07-15 JP¥280.00 +7.28% 1,898,200
26-07-14 JP¥261.00 -1.14% 847,300
26-07-13 JP¥264.00 +1.15% 1,229,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
256.00JPY
Average target price
779.83JPY
Spread / Average Target
+204.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock